Political Quotes

Louise Slaughter: Today, the House votes on the biggest change in Medicare in its 40-year history, a change that will affect 40 million…

On the recordJune 26, 2003
Today, the House votes on the biggest change in Medicare in its 40-year history, a change that will affect 40 million Americans; but the Republican leaders have rigged the rules to prevent the House from voting on serious alternatives offered by Republicans and Democrats alike. I will call for a ``no'' vote on the previous question in the hope that the House gets the chance to consider an additional alternative that the Republican leaders fear. If the previous question is defeated, I will offer an amendment to the rule that will make in order the Dooley prescription drug alternative substitute. It makes all senior citizens enrolled in Medicare part B eligible for prescription drug assistance without increasing their premiums. Unlike the Republican bill, it has no sickness penalty or doughnut hole that seniors can fall through. Unlike the Republican bill, it does not encourage companies to drop seniors' existing drug plans. Let me make it clear that a ``no'' vote on the previous question will not stop the consideration of H.R. 1. It will simply allow the House to vote on the Dooley substitute. However, a ``yes'' vote on the previous question will prevent the House from voting. I urge a ``no'' vote.
Said by
Louise Slaughter
New York

Editor's note · Context

Addressing the House on proposed changes to Medicare and urging a vote against the previous question.

Share

More from Louise Slaughter

Oct 22, 2013

These are victims in the strongest sense of the word, the children who have been preyed upon by those who would take advantage of the situation.

congress.gov
Oct 22, 2013

To say that I am completely appalled and embarrassed by that number is an understatement.

congress.gov
May 15, 2017

We will do incalculable harm if we did not keep that going, and we are better people than that.

congress.gov
Mar 17, 2021

I am really excited about the opportunity to take a fresh look at a broader range of questions in pharmaceutical mergers than our traditional approach has taken.

congress.gov

Other voices in this conversation